Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

Quark Venture and GF Securities invest US$25 million in Microbion to advance a new class of drugs that combat antibiotic-resistant infections

Fasken
Reading Time 1 minute read Subscribe
Client

Quark Venture

Quark Venture and GF Securities announced a US$25 million investment in Microbion Corporation through its Global Health Sciences Venture Fund. The investment will enable Microbion to initiate and complete a Phase 1B/2A study in diabetic foot ulcer infections evaluating both safety and efficacy endpoints including eradication of infections and of biofilms. Quark Venture, a Vancouver-based health sciences venture capital company, is focused on equity financing of innovative biotechnology and health sciences companies with breakthrough technology platforms and projects. Microbion, a clinical stage biopharmaceutical company, is developing MBN-101 as the first product in a new class for the treatment of resistant and difficult to treat infections. Fasken Martineau was counsel to Quark Venture with a team led by Roger Kuypers that included Jon Conlin and Jasmin Zeng.

    Subscribe

    Receive email updates from our team

    Subscribe